Pain and Inflammation Article

Article Summary:
This systematic review aimed to assess the effectiveness of cannabidiol (CBD) in managing chronic pain, synthesizing evidence from 15 studies involving 1,516 articles identified through eight databases and gray literature sources. The review followed PRISMA 2020 guidelines, assessing studies published until August 2022. Results indicated that CBD, used alone or with tetrahydrocannabinol, reduced chronic pain by 42% to 66% in many cases, although some studies showed mixed or insignificant results. Outcome measures varied, predominantly using self-reporting and pain scales. The review concludes that while CBD shows promise for chronic pain management, more robust studies are needed to validate its efficacy due to study design heterogeneity and limited research volume.